Velaglucerase Alfa
Gaucher Disease, Type 1
Shaare Zedek Medical Centerprotein_peptidePhase 4 / ApprovedDormant
A
81/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 71/ 100
- Competitive Position
- 95/ 100
Competitive context
4 Active assets in the Gaucher Disease, Type 1 cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Cerezyme Genzyme, a Sanofi Company | Phase 4 | A |
Eliglustat Genzyme, a Sanofi Company | Phase 3 | BBB |
ISOFAGOMINE Amicus Therapeutics | Phase 2 | BB |
isu302 ISU Abxis Co., Ltd. | Phase 3 | BB |
Ambroxol Shaare Zedek Medical Center | Phase 2 | B |
View all 11 →
Same molecule, other indications
Velaglucerase Alfa is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →